Toggle menu

LAVAS Study

Start date:
Historic
End date:
June 2014
Co-ordinated by:
NHS Lothian

Lactate, Arterial and Venous Agreement in Sepsis – LAVAS trial

Aim

To determine whether an agreement between peripheral venous and arterial lactate exists in patients presenting to an Emergency Department with sepsis.

Trial Design

A prospective observational study in a consecutive sample of eligible and consented patients in the Royal Infirmary of Edinburgh

Eligibility criteria (summary)

Patients who present to the Emergency Department with suspected sepsis

Chief Investigator

Dr Deepankar Datta

Specialist Trainee Emergency Medicine

Local PI

Dr Deepankar Datta

Specialist Trainee Emergency Medicine

Research Team

Julia Grahamslaw

Lead Research Nurse

More EMERGE Trials

The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.

The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.  

This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.

Participants will be asked to return for 6 visits across 12 months to evaluate their health.

Across the UK the trial aims to recruit 10,260 volunteers.

If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh

Read more

COV_002 Vaccine Trial

The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)